CORE Diagnostics, a next-generation startup and go-to-expert for high-end clinical diagnostics, well known for it’s oncology (cancer-related) diagnostics, announced the launch of it’s division for advanced diagnostic services in nephrology called “nephroCORE”. These services will ensure best clinical intervention to improve outcomes in several chronic and generic kidney diseases including kidney transplants.  

CORE’s new addition of nephrology related diagnostic tests comprises of advanced nephro-pathology services, molecular testing for rare and inherited (genetic) kidney diseases, screening for pre and post-transplant infectious diseases, monitoring drug levels, and Transplant Immunology. Very few laboratories in India provide such services and expertise. 

On the occasion of the launch, Zoya Brar, Founder & MD, CORE Diagnostics said “We want to bring back the focus on the unmet need to diagnose and treat kidney disease earlier in order to slow the progression of the disease. Unsuccessful or inadequate clinical intervention can impose a heavy financial burden on patients. Kidney disease is considered a silent disease; most cases are diagnosed in later stages. We are confident that with the newest addition of nephrology diagnostic services, we will improve the healthcare outcomes and quality of lives of the patients we serve.”

Within a span of one month, CORE has already reported over 200 cases of native and transplant kidney biopsies from across India and a few international territories. “Kidney biopsies are the gold-standard for the diagnosis of medical and transplant kidney disorders. At CORE, we run the rarest of high-end diagnostic markers on renal biopsy samples that help us come up with a definitive diagnosis along with prognostic information for the treating physician,” commented Dr. Rajan Duggal, Vice President nephro CORE.  Dr. Duggal has around ten years of experience in renal pathology. Prior to working at CORE, he was at PGIMER Chandigarh, Medanta Medicity, and Fortis Hospitals and has seen over 10,000 kidney biopsies to date.